PE20171624A1 - Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral - Google Patents
Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviralInfo
- Publication number
- PE20171624A1 PE20171624A1 PE2017001530A PE2017001530A PE20171624A1 PE 20171624 A1 PE20171624 A1 PE 20171624A1 PE 2017001530 A PE2017001530 A PE 2017001530A PE 2017001530 A PE2017001530 A PE 2017001530A PE 20171624 A1 PE20171624 A1 PE 20171624A1
- Authority
- PE
- Peru
- Prior art keywords
- fluorine substituted
- antiviral treatment
- nucleosid
- analogs
- substituted carba
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 229910052731 fluorine Inorganic materials 0.000 title 1
- 239000011737 fluorine Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 nucleoside phosphates Chemical class 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171624A1 true PE20171624A1 (es) | 2017-11-02 |
Family
ID=47748238
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001530A PE20171624A1 (es) | 2010-09-20 | 2011-03-22 | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral |
| PE2022003082A PE20230684A1 (es) | 2010-09-20 | 2011-03-22 | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa |
| PE2013000530A PE20131165A1 (es) | 2010-09-20 | 2011-03-22 | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022003082A PE20230684A1 (es) | 2010-09-20 | 2011-03-22 | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa |
| PE2013000530A PE20131165A1 (es) | 2010-09-20 | 2011-03-22 | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2619206A1 (enExample) |
| JP (4) | JP2013538230A (enExample) |
| KR (1) | KR101879887B1 (enExample) |
| CN (1) | CN103108876A (enExample) |
| AP (1) | AP3699A (enExample) |
| AU (1) | AU2011306066B2 (enExample) |
| BR (1) | BR112013008017A2 (enExample) |
| CA (1) | CA2807496C (enExample) |
| CL (1) | CL2013000727A1 (enExample) |
| CO (1) | CO6680669A2 (enExample) |
| CR (1) | CR20130172A (enExample) |
| EA (1) | EA026523B1 (enExample) |
| EC (1) | ECSP13012560A (enExample) |
| IL (1) | IL225221A0 (enExample) |
| MA (1) | MA34593B1 (enExample) |
| MX (1) | MX2013003179A (enExample) |
| NZ (1) | NZ608070A (enExample) |
| PE (3) | PE20171624A1 (enExample) |
| PH (1) | PH12013500311B1 (enExample) |
| SG (1) | SG188223A1 (enExample) |
| WO (1) | WO2012039791A1 (enExample) |
| ZA (1) | ZA201301042B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP3076A (en) | 2008-04-23 | 2014-12-31 | Gilead Sciences Inc | Carba-nucleoside analogs for antiviral treatment |
| EP2480559B1 (en) | 2009-09-21 | 2013-07-03 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs |
| EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| TW201701876A (zh) | 2010-12-20 | 2017-01-16 | 吉李德科學股份有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| EP3650013A1 (en) | 2013-01-31 | 2020-05-13 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| CN104230985B (zh) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法 |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| PL3349758T3 (pl) | 2015-09-16 | 2022-09-12 | Gilead Sciences, Inc. | Sposoby leczenia zakażeń wirusami arenaviridae |
| KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| IL300453A (en) * | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| KR20250007533A (ko) | 2022-04-08 | 2025-01-14 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물 |
| JP2025514335A (ja) * | 2022-04-25 | 2025-05-02 | 北京沐華生物科技有限責任公司 | コロナウイルス感染症を治療又は予防するためのヌクレオシド系薬物及びその使用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| PL364995A1 (en) | 2000-02-18 | 2004-12-27 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| PT2251015E (pt) | 2000-10-18 | 2013-04-15 | Gilead Pharmasset Llc | Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal |
| BR0206614A (pt) * | 2001-01-22 | 2004-02-17 | Merck & Co Inc | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto |
| US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| ES2586668T5 (es) * | 2003-05-30 | 2024-11-12 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| AU2005317081A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| SI2114980T1 (sl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Protivirusni nukleozidni analogi |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP2011513195A (ja) | 2007-05-10 | 2011-04-28 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ウイルス感染およびがんの処置に使用するためのテトラヒドロフロ［３，４−ｄ］ジオキソラン化合物 |
| AP3076A (en) * | 2008-04-23 | 2014-12-31 | Gilead Sciences Inc | Carba-nucleoside analogs for antiviral treatment |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| CN102348713B (zh) * | 2009-02-10 | 2015-12-02 | 吉里德科学公司 | 用于抗病毒治疗的carba-核苷类似物 |
| EA201200525A1 (ru) * | 2009-09-21 | 2012-09-28 | Гайлид Сайэнсиз, Инк. | 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения |
-
2011
- 2011-03-22 CA CA2807496A patent/CA2807496C/en active Active
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 PH PH1/2013/500311A patent/PH12013500311B1/en unknown
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active Application Discontinuation
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/en not_active Withdrawn
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active Active
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/en not_active Ceased
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019014726A (ja) | 2019-01-31 |
| MX2013003179A (es) | 2013-04-24 |
| WO2012039791A1 (en) | 2012-03-29 |
| BR112013008017A2 (pt) | 2016-06-14 |
| CR20130172A (es) | 2013-05-29 |
| CA2807496A1 (en) | 2012-03-29 |
| JP2017119726A (ja) | 2017-07-06 |
| CN103108876A (zh) | 2013-05-15 |
| KR20130110168A (ko) | 2013-10-08 |
| JP2016074732A (ja) | 2016-05-12 |
| AU2011306066B2 (en) | 2015-01-29 |
| ZA201301042B (en) | 2014-07-30 |
| SG188223A1 (en) | 2013-04-30 |
| PE20230684A1 (es) | 2023-04-21 |
| EP2619206A1 (en) | 2013-07-31 |
| EA201390141A1 (ru) | 2013-09-30 |
| CA2807496C (en) | 2019-01-22 |
| NZ608070A (en) | 2015-11-27 |
| IL225221A0 (en) | 2013-06-27 |
| AP3699A (en) | 2016-05-31 |
| AU2011306066A1 (en) | 2013-02-28 |
| PE20131165A1 (es) | 2013-10-14 |
| JP6475280B2 (ja) | 2019-02-27 |
| EA026523B1 (ru) | 2017-04-28 |
| KR101879887B1 (ko) | 2018-07-18 |
| PH12013500311A1 (en) | 2013-04-22 |
| MA34593B1 (fr) | 2013-10-02 |
| JP2013538230A (ja) | 2013-10-10 |
| PH12013500311B1 (en) | 2017-11-08 |
| AP2013006767A0 (en) | 2013-03-31 |
| ECSP13012560A (es) | 2013-06-28 |
| CO6680669A2 (es) | 2013-05-31 |
| CL2013000727A1 (es) | 2013-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171624A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| CR20190103A (es) | ANÁLOGOS DE CARBA-NUCLEÓSIDOS SUSTITUIDOS CON 2'-FLUORO PARA TRATAMIENTO ANTIVIRAL (Divisional 2012-0186) | |
| EA201691623A1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral | |
| MX2013011915A (es) | Analogos del n-nucleosido de pirimidina 1'-sustituida para tratamiento antiviral. | |
| CO6420354A2 (es) | Análogos de carba-nucleósido para tratamiento antiviral | |
| UY33414A (es) | ?profármacos de nucleósidos 1'?carba sustituidos para tratamiento antiviral, composiciones y su uso?. | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| CA2807584C (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| ECSP088518A (es) | Nucleósidos antivirales | |
| EA201500304A1 (ru) | Аналоги 2'-хлоро нуклеозидов для инфекции вгс | |
| ECSP13012451A (es) | Métodos para la preparación de profármacos de fosforamidato diastereoméricamente puros | |
| CO6690740A2 (es) | Métodos y compuestos para tratar infecciones virales por paramyxoviridae | |
| NZ631182A (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
| UA102687C2 (ru) | 1'-замещенные карбануклеозидные аналоги для противовирусной терапии | |
| TH145025A (th) | สารที่มีโครงสร้างคล้ายคาร์บา-นิวคลีโอไซด์ที่มีการแทนที่ 2'-ฟลูออโรสำหรับการรักษาด้วยสารต้านไวรัส | |
| TH148539A (th) | สารคล้ายคาร์บา-นิวคลิโอไซด์ที่ถูกแทนที่ที่ตำแหน่ง 1' สำหรับการบำบัดต้านไวรัส | |
| NI200600301A (es) | Nucleosidos antivirales. |